CD274 and small cell lung carcinoma: For example, a preclinical study showed that combined anti-VEGF/anti-PD-L1 targeted therapy synergistically improves the treatment outcome, compared to both anti-PD-L1 or anti-VEGF monotherapy in an autochthonous mouse model of small cell lung cancer (SCLC) (213).